Fenfluramine
| Fenfluramine | |
|---|---|
| Salts [] | |
|---|---|
| Fenfluramine hydrochloride | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 231.26 g/mol [1] |
| Melting point | 160-170 [1] |
| Boiling point | 108-112 [1] |
| Decomposition | When heated to decomp it emits very toxic fumes of fluoride ion and oxides of nitrogen. [1] |
| Solubility | 412 mg/L [1] |
| Predicted LogP | 3.4 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C12H16F3N |
| IUPAC name | N-ethyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine |
| SMILES | CCNC(C)CC1=CC(=CC=C1)C(F)(F)F |
| InChI | InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3 |
| InChIKey | DBGIVFWFUFKIQN-UHFFFAOYSA-N |
| CAS number | 458-24-2 |
| UNII | 2DS058H2CF |
| PubChem CID | 3337 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 13–30 hours |
| Routes of administration | By mouth |
Fenfluramine (also known as Obedrex, Rotondin, Pesos, DL-Fenfluramine, Ponderax PA, Fenfluramina, Acino, Fenfluraminum, (+-)-Fenfluramine or Fenfluramin) is a substance of the amphetamine class.
Chemistry
Salts []
Stereochemistry []
Fenfluramine is a racemic mixture of the enantiomers (optical activity ( + / - )).
| Stereoisomerism |
|---|
| Stereoisomers from PubChem |
Druglikeness
Lipinski's rule of five
Fenfluramine matches Lipinski's rule of five.Pharmacology
ATC Classification
- alimentary tract and metabolism (A)
- antiobesity preparations, excl. diet products (A08)
- antiobesity preparations, excl. diet products (A08A)
- centrally acting antiobesity products (A08AA)
- fenfluramine (A08AA02)
- nervous system (N)
- antiepileptics (N03)
- antiepileptics (N03A)
- other antiepileptics (N03AX)
- fenfluramine (N03AX26)
MeSH Classification
Mechanism of action []
Dravet syndrome is a complex pediatric encephalopathy characterized by recurrent pharmacoresistant seizures of variable type, delayed development, and in many cases, impairment in speech, language, gait, and other neurocognitive functions. Despite substantial variation in presentation and severity, roughly 80% of patients with Dravet syndrome have mutations in the _SCN1A_ gene, which encodes the alpha subunit of a voltage-gated sodium channel (Na<sub>v</sub>1.1). This channel is predominantly localized in inhibitory GABAergic interneurons as well as in excitatory pyramidal neurons; it is thought that dysfunction of neurotransmission regulation results in the seizures and other corresponding symptoms of Dravet syndrome. Various _in vitro_ and _in vivo_ studies have demonstrated that fenfluramine is capable of acting as an agonist of multiple serotonin receptors including 5-HT<sub>1A</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub>, as well as a σ1 receptor antagonist. This is at least partly because fenfluramine, as well as its active metabolite norfenfluramine, can act on sodium-dependent serotonin transporters (SERTs) to reverse transport direction and thereby increase extracellular serotonin levels. However, work in animal models of Dravet syndrome suggest that only the modulation of 5-HT<sub>1D</sub>, 5-HT<sub>2C</sub>, σ1, and possibly 5-HT<sub>2A</sub> receptors of fenfluramine result in the anti-epileptiform activity. Interestingly, 5-HT<sub>2B</sub> receptor agonism, which had previously been associated with cardiac valvulopathy, is not anticipated to have any therapeutic value in Dravet syndrome. Although the exact mechanism by which stimulation/inhibition of various receptors leads to the observed therapeutic benefit is unclear, it is hypothesized to be two-fold. Stimulation of 5-HT<sub>1D</sub> and 5-HT<sub>2C</sub> may result in increased GABAergic neurotransmission, while σ1 receptor antagonism may help to modulate responses to _N_-methyl-D-aspartate (NMDA). [1]
Interactions []
Interaction mechanisms documented in KEGG DRUG (number of interacting drugs):
| CYP3A4 | metabolism / inhibition / induction | 231 (2 contraindicated) |
|---|---|---|
| CYP2D6 | metabolism / inhibition / induction | 168 (5 contraindicated) |
| CYP2C19 | metabolism / inhibition / induction | 79 (2 contraindicated) |
| CYP1A2 | inhibition / metabolism / induction | 76 (3 contraindicated) |
| SLC6A4 | shared target | 55 |
| CYP2B6 | metabolism / induction / inhibition | 54 (2 contraindicated) |
| CYP3A5 | metabolism / inhibition | 17 |
| HTR1D | shared target | 17 |
| HTR2A | shared target | 15 |
| HTR2C | shared target | 8 |
| SIGMAR1 | shared target | 2 |
Legal status []
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 3337, Fenfluramine. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3337
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Fenfluramine. UNII: 2DS058H2CF. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/2DS058H2CF
RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 24 July 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-804-de-24-de-julho-de-2023-498447451
Fintepla EPAR. European Medicines Agency (EMA). 13 October 2020. https://www.ema.europa.eu/en/medicines/human/EPAR/fintepla
Fintepla Product information. Union Register of medicinal products. https://ec.europa.eu/health/documents/community-register/html/h1491.htm
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 13:00:58 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 13:00:54 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 13:00:54 |
| gsrs | ok | 2026-11-20 13:00:55 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0252200) | 2026-11-20 13:00:54 |
| kegg | ok | 2026-11-20 13:00:58 |
| pubchem | ok | 2026-11-20 13:00:52 |
| missing (no r/tripreports posts mention it) | 2026-11-20 13:00:54 | |
| sider | missing (not in SIDER) | 2026-11-20 13:00:54 |
| structure | ok | 2026-11-20 13:00:54 |
| wikipedia | ok | 2026-11-20 13:00:54 |